The Implication of TP53 Allelic Status for Outcome and Erythropoiesis in MDS
Li B, Zeng Y, Li C, Liu J, Song G, Yao Y, Zeidan A, Xiao Z. The Implication of TP53 Allelic Status for Outcome and Erythropoiesis in MDS. Blood 2024, 144: 6707-6707. DOI: 10.1182/blood-2024-205429.Peer-Reviewed Original ResearchNext-generation sequencingMultiplex ligation-dependent probe amplificationComplex karyotypeMyelodysplastic syndromeCD34+ cellsPrognostic impactClinical characteristicsBone marrowPercentage of erythroid progenitorsCD34+ BM cellsAllele statusSubtype of myelodysplastic syndromeLigation-dependent probe amplificationTP53-mutant patientsPercentage of blastsSingle-cell mutational analysisCopy number assayCopy number alterationsClone sizeLineage dysplasiaMutant patientsTP53 mutationsBM cellsMDS-UWHO classificationIntegrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine
Zeidan A, Bewersdorf J, Hasle V, Shallis R, Thompson E, de Menezes D, Rose S, Boss I, Halene S, Haferlach T, Fox B. Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine. Therapeutic Advances In Hematology 2024, 15: 20406207241257904. PMID: 38883163, PMCID: PMC11180421, DOI: 10.1177/20406207241257904.Peer-Reviewed Original ResearchHigher-risk myelodysplastic syndromesAcute myeloid leukemiaBone marrowMutation statusImmune landscapeImmunological landscapeAnti-PD-L1 antibody durvalumabHR-MDS patientsWild-type acute myeloid leukemiaTP53-mutant acute myeloid leukemiaMutant acute myeloid leukemiaAzacitidine-based therapyWild-type patientsImmune checkpoint proteinsImmune checkpoint expressionT cell populationsWild-typeStatistically significant decreaseAZA therapyImmunosuppressive microenvironmentPD-L1Mutant patientsDNA methylation arraysCheckpoint expressionMyelodysplastic syndrome